Back to search

Article

Rapid resistance profiling of SARS-CoV-2 protease inhibitors

2023-03-15

Abstract excerpt

<title>Abstract</title> <p>Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (Mpro) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms (“fingerprints”) and indicate that thes...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1ea32ac5-0c46-5661-a544-aac39dd74dc7
DOI
10.21203/rs.3.rs-2627723/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Rapid resistance profiling of SARS-CoV-2 protease inhibitorsDOI 10.21203/rs.3.rs-2627723/v1
Rapid resistance profiling of SARS-CoV-2 protease inhibitorsSemantic proximity
Rapid resistance profiling of SARS-CoV-2 protease inhibitorsSemantic proximity
A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.Semantic proximity
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity
Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity
The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor <i>in vitro</i> and confer resistance to nirmatrelvirSemantic proximity
An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV-2 MproSemantic proximity
Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main proteaseSemantic proximity
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity
Select a neighboring publication to make it the new centre.